Recursion Pharmaceuticals annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Recursion Pharmaceuticals Depreciation & Amortization Growth & History (RXRX)
Recursion Pharmaceuticals's depreciation and amortization was $83.7M for fiscal 2025.
View full Recursion Pharmaceuticals company overviewRecursion Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $83.7M | $47.2M | +129.36% |
| 2024 | 2024-12-31 | $36.5M | $12.1M | +49.55% |
| 2023 | 2023-12-31 | $24.4M | $12.6M | +107.57% |
| 2022 | 2022-12-31 | $11.8M | $3.4M | +39.87% |
| 2021 | 2021-12-31 | $8.4M | $4.5M | +113.16% |
| 2020 | 2020-12-31 | $3.9M | $1.5M | +58.42% |
| 2019 | 2019-12-31 | $2.5M | — | — |
Recursion Pharmaceuticals quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18.2M | −$5.7M | −23.82% |
| Q1 2026 | 2026-03-31 | $19.7M | $342,000 | +1.77% |
| Q4 2025 | 2025-12-31 | $19.5M | — | — |
| Q3 2025 | 2025-09-30 | $21.0M | $13.8M | +192.35% |
| Q2 2025 | 2025-06-30 | $23.8M | $14.9M | +165.93% |
| Q1 2025 | 2025-03-31 | $19.3M | $12.0M | +162.04% |
| Q3 2024 | 2024-09-30 | $7.2M | −$380,000 | −5.01% |
| Q2 2024 | 2024-06-30 | $9.0M | $3.4M | +61.79% |
| Q1 2024 | 2024-03-31 | $7.4M | $3.6M | +97.88% |
| Q3 2023 | 2023-09-30 | $7.6M | $4.6M | +153.53% |
| Q2 2023 | 2023-06-30 | $5.5M | $2.8M | +98.96% |
| Q1 2023 | 2023-03-31 | $3.7M | $961,000 | +34.73% |
| Q3 2022 | 2022-09-30 | $3.0M | $553,000 | +22.70% |
| Q2 2022 | 2022-06-30 | $2.8M | $455,000 | +19.52% |
| Q1 2022 | 2022-03-31 | $2.8M | $1.4M | +97.36% |
| Q3 2021 | 2021-09-30 | $2.4M | $1.6M | +184.25% |
| Q2 2021 | 2021-06-30 | $2.3M | $1.3M | +127.64% |
| Q1 2021 | 2021-03-31 | $1.4M | $465,000 | +49.63% |
| Q3 2020 | 2020-09-30 | $857,000 | — | — |
| Q2 2020 | 2020-06-30 | $1.0M | — | — |
| Q1 2020 | 2020-03-31 | $937,000 | — | — |
Recursion Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Recursion Pharmaceuticals's depreciation and amortization increased from $3.9M to $83.7M, a change of $79.8M. The latest reported quarter, Q2 2026, shows $18.2M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Recursion Pharmaceuticals source filings ↗